About PC Diagnostics
PC Diagnostics is a publicly listed company based in Mumbai (India) founded in 2016. It offers pathology, imaging, and cardiology services through diagnostic centers in India. It operates on a B2C and D2C model. The company has 1 employees. Its Indian entity Invicta Diagnostic Limited reported revenue of ₹30.66 Cr. PC Diagnostics offers products and services including Ultrasound, X-Ray, Pathology, CT Scan, and MRI Scan. Its focus areas include Diagnostics, Pathology, Laboratory Testing and Medical Imaging. Its competitors include Thyrocare, Vijaya Diagnostic Centre, Suraksha Diagnostics, Igenetic and Krsnaa Diagnostics and 5 more; 7 of its 10 listed competitors have raised funding.
Company details
PC Diagnostics delivers preventive health check-ups and diagnostic services, including pathology, imaging, and non-invasive cardiology. They operate centers across Mumbai, with affiliations to hospitals, ensuring accurate tests for full body check-ups and home blood services. Serving doctors and patients in India, they focus on advancements in diagnostics for reliable health outcomes.
- Headquarters Mumbai, India
- Employees 1
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website pcdiagnostics.in
- Legal Name Invicta Diagnostic Limited
- Market Cap₹86.75 Cr
INVICTA-SM · NSE
- Share Price₹69.00
0.00% today
- Revenue₹32.35 Cr
FY 2025-26 · +7.5% YoY
- EBITDA₹9.75 Cr
Margin 30.1%
- Net Profit₹4.44 Cr
FY 2025-26 · -9.4% YoY
- P/E (TTM)19.5x
P/B 1.7x
- ROE15.3%
ROCE 20.3%
- Debt / Equity0.11
Interest cover 3.1x
- Employee Count1
Associated legal entities of PC Diagnostics
PC Diagnostics is associated with 6 registered companies on The Company Check; the primary company is Invicta Diagnostic Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Invicta Diagnostic Limited Listed CIN L86100MH2023PLC414723 | Active | 01 Dec 2023 | Mumbai, Maharashtra | ₹30.7 Cr | 1 | 6 | View details |
| Invicta Diagnostic Limited CIN U86100MH2023PLC414723 | Active | 01 Dec 2023 | Mumbai, Maharashtra, India | – | – | – | View details |
| Primacare Healthcare Llp CIN AAN-6805 | Active | 10 Dec 2018 | Mumbai, Maharashtra | ₹4.8 Cr | – | 2 | View details |
| Mscribeit Infotech Llp CIN ABZ-1385 | Active | 21 Nov 2022 | Mumbai, Maharashtra | – | – | 2 | View details |
| Invicta Diagnostic Llp CIN AAV-5564 | Converted And Dissolved | 22 Jan 2021 | Mumbai, Maharashtra | – | – | 10 | View details |
| Pcd Diagnostics Llp CIN ABA-5776 | Active | 09 Feb 2022 | Mumbai, Maharashtra | ₹3.0 Cr | – | 2 | View details |
Products & Services of PC Diagnostics
PC Diagnostics offers a comprehensive portfolio of products and services, including Ultrasound, X-Ray, Pathology, CT Scan, and MRI Scan.
Provides diagnostic imaging for internal body structures.
Offers radiographic imaging for bone and tissue examination.
Conducts tests for disease diagnosis through sample analysis.
Delivers detailed cross-sectional images of the body.
Uses magnetic fields for detailed soft tissue diagnostics.
Provides metabolic imaging for detecting abnormalities.
Offers non-invasive tests for heart health monitoring.
Board of directors of Invicta Diagnostic Limited (PC Diagnostics)
Invicta Diagnostic Limited is the primary company behind PC Diagnostics. The boards of the 5 registered companies of PC Diagnostics currently have 13 directors; the longest-serving is Badal Kailash Naredi, appointed in 2018. 27 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Badal Kailash Naredi DIN 01692192 | Designated Partner | 10 Dec 2018 | 7 yrs 10 mo | Primacare Healthcare Llp, Invicta Diagnostic Llp |
| Monal Ketan Jain DIN 08299040 | Partner | 22 Jan 2021 | 5 yrs 8 mo | Invicta Diagnostic Llp |
| Dipika Jayantilal Jain DIN 07819221 | Partner | 22 Jan 2021 | 5 yrs 8 mo | Invicta Diagnostic Llp |
| Kushal Wayunandan Koli DIN 09180826 | Designated Partner | 21 May 2021 | 5 yrs 4 mo | Invicta Diagnostic Llp |
| Jayesh Prakash Jain DIN 08359998 | Designated Partner | 21 May 2021 | 5 yrs 4 mo | Invicta Diagnostic Llp |
| Amol Purushottam Khandelwal DIN 02638425 | Designated Partner | 21 May 2021 | 5 yrs 4 mo | Invicta Diagnostic Llp |
| Konica Ravi Seal DIN 07786137 | Partner | 16 Aug 2023 | 3 yrs 2 mo | Invicta Diagnostic Llp |
| Kunal Anil Jain DIN 08360043 | Designated Partner | 16 Aug 2023 | 3 yrs 2 mo | Invicta Diagnostic Llp, Pcd Diagnostics Llp |
| Ketan Jayantilal Jain DIN 07819226 | Partner | 16 Aug 2023 | 3 yrs 2 mo | Invicta Diagnostic Llp, Invicta Diagnostic Limited |
| Aayush Kamleshbhai Shah DIN 10149440 | Director | 12 Jul 2024 | 2 yrs 3 mo | Invicta Diagnostic Limited |
| Shilpa Ajay Bhatia DIN 10377934 | Director | 12 Jul 2024 | 2 yrs 3 mo | Invicta Diagnostic Limited |
| Sanket Vinod Jain DIN 08299039 | Designated Partner | 15 Apr 2025 | 1 yr 6 mo | Primacare Healthcare Llp, Invicta Diagnostic Llp, Pcd Diagnostics Llp, Mscribeit Infotech Llp, Invicta Diagnostic Limited |
| Anubhuti Amol Khandelwal DIN 10808474 | Designated Partner | 19 May 2025 | 1 yr 5 mo | Mscribeit Infotech Llp |
IPO & Listings of PC Diagnostics
PC Diagnostics is a publicly listed company on the NSE with ticker symbol INVICTA in India. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Dec 2025
- Listed onNSE: INVICTA
- Listed entityInvicta Diagnostic limited
- ISININE0XJ501010
- Share price₹64.50 (-2.27% on the day) · 2026-10-12
- Volume (last session)3,200
Financials of PC Diagnostics
Exchange-reported figures of Invicta Diagnostic Limited, the listed company behind PC Diagnostics (NSE: INVICTA-SM).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 32.35 | 30.10 | 7.99 |
| Revenue growth | +7.5% | +276.7% | - |
| EBITDA | 9.75 | 9.21 | 3.39 |
| EBITDA margin | +30.1% | +30.6% | +42.4% |
| Profit before tax | 6.99 | 6.58 | 2.68 |
| Net profit | 4.44 | 4.90 | 2.68 |
| Net profit margin | +13.7% | +16.3% | +33.5% |
| EPS (₹) | 3.90 | 5.81 | 204.49 |
| Balance sheet | |||
| Total assets | 53.70 | 17.23 | 13.01 |
| Net worth | 49.92 | 13.60 | 12.18 |
| Total debt | 3.67 | 3.53 | 1.87 |
| Cash & bank | 22.21 | 2.16 | 1.34 |
| Net working capital | 29.57 | 3.69 | 1.47 |
| Cash flow | |||
| Cash from operations | 2.93 | 6.56 | 4.21 |
| Cash from investing | (13.67) | (5.23) | (10.01) |
| Cash from financing | 30.79 | (0.50) | 7.14 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 20.28 | 16.27 | 3.50 |
| Revenue growth | +24.7% | +364.9% | - |
| EBITDA | 7.66 | 6.20 | 1.47 |
| EBITDA margin | +37.8% | +38.1% | +42.0% |
| Profit before tax | 7.26 | 6.68 | 2.42 |
| Net profit | 5.10 | 5.22 | 2.40 |
| Net profit margin | +25.2% | +32.1% | +68.6% |
| EPS (₹) | 4.40 | 6.21 | 182.53 |
| Balance sheet | |||
| Total assets | 49.20 | 14.73 | 9.43 |
| Net worth | 49.09 | 12.78 | 9.43 |
| Total debt | 0.00 | 1.86 | 0.00 |
| Cash & bank | 21.21 | 0.80 | 0.89 |
| Net working capital | 25.42 | 2.91 | 0.89 |
| Cash flow | |||
| Cash from operations | 3.20 | 2.79 | 5.05 |
| Cash from investing | (12.60) | (2.75) | (9.51) |
| Cash from financing | 29.80 | (0.12) | 5.35 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 32.35 | 30.10 | 7.99 |
| Revenue growth | +7.5% | +276.7% | - |
| Other income | 0.69 | 0.09 | 0.35 |
| Total expenses | 22.60 | 20.89 | 4.60 |
| Employee cost | 4.77 | 4.69 | 1.09 |
| EBITDA | 9.75 | 9.21 | 3.39 |
| EBITDA margin | +30.1% | +30.6% | +42.4% |
| Depreciation | 3.25 | 2.49 | 0.98 |
| Interest | 0.20 | 0.23 | 0.08 |
| Profit before tax | 6.99 | 6.58 | 2.68 |
| Tax | 2.13 | 1.64 | 0.00 |
| Net profit | 4.44 | 4.90 | 2.68 |
| Net profit margin | +13.7% | +16.3% | +33.5% |
| EPS (₹) | 3.90 | 5.81 | 204.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 12.57 | 8.42 | 0.13 |
| Reserves & surplus | 37.35 | 5.18 | 12.05 |
| Shareholders' funds (net worth) | 49.92 | 13.60 | 12.18 |
| Minority interest | 0.00 | 0.00 | (1.03) |
| Secured loans | 3.67 | 1.57 | 1.87 |
| Unsecured loans | 0.00 | 1.96 | 0.00 |
| Total debt | 3.67 | 3.53 | 1.87 |
| Total liabilities | 53.70 | 17.23 | 13.01 |
| Assets | |||
| Gross block | 33.95 | 21.09 | 17.22 |
| Net block | 19.20 | 9.58 | 11.79 |
| Capital work in progress | 0.00 | 0.00 | 0.00 |
| Investments | 6.20 | 4.33 | 0.00 |
| Inventories | 0.59 | 0.50 | 0.39 |
| Sundry debtors | 0.57 | 1.46 | 0.82 |
| Cash & bank balances | 22.21 | 2.16 | 1.34 |
| Loans & advances | 10.93 | 2.27 | 1.16 |
| Total current assets | 34.30 | 6.39 | 3.71 |
| Total current liabilities | 4.73 | 2.70 | 2.24 |
| Net working capital | 29.57 | 3.69 | 1.47 |
| Total assets | 53.70 | 17.23 | 13.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 2.16 | 1.34 | 0.00 |
| Net cash from operating activities | 2.93 | 6.56 | 4.21 |
| Net cash from investing activities | (13.67) | (5.23) | (10.01) |
| Net cash from financing activities | 30.79 | (0.50) | 7.14 |
| Net change in cash | 20.05 | 0.83 | 1.34 |
| Closing cash | 22.21 | 2.16 | 1.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +7.5% | +276.7% | - |
| EBITDA growth | +5.9% | +171.7% | - |
| PBT growth | +6.2% | +145.5% | +9997.0% |
| Net income growth | -9.4% | +82.8% | - |
| Profitability & leverage | |||
| Net income margin | +15.0% | +16.4% | +33.5% |
| Return on capital employed | +20.3% | +43.4% | +19.7% |
| Return on net worth | +15.3% | +38.3% | +22.1% |
| Debt / equity | 0.11 | 0.21 | 0.15 |
| Long-term debt / equity | 0.03 | 0.08 | 0.00 |
| Interest cover | 3.08 | 3.42 | 3.32 |
| Efficiency & per share | |||
| Fixed asset turnover | 1.18 | 1.57 | 0.46 |
| Inventory turnover | 59.36 | 67.64 | 20.49 |
| Debtors turnover | 31.87 | 26.40 | 9.74 |
| EPS (₹) | 3.90 | 5.81 | 204.49 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 39.71 | 16.15 | 925.99 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 20.28 | 16.27 | 3.50 |
| Revenue growth | +24.7% | +364.9% | - |
| Other income | 1.13 | 1.46 | 1.34 |
| Total expenses | 12.62 | 10.07 | 2.03 |
| Employee cost | 2.81 | 2.36 | 0.61 |
| EBITDA | 7.66 | 6.20 | 1.47 |
| EBITDA margin | +37.8% | +38.1% | +42.0% |
| Depreciation | 1.49 | 0.95 | 0.38 |
| Interest | 0.04 | 0.03 | 0.01 |
| Profit before tax | 7.26 | 6.68 | 2.42 |
| Tax | 1.73 | 1.46 | 0.02 |
| Net profit | 5.10 | 5.22 | 2.40 |
| Net profit margin | +25.2% | +32.1% | +68.6% |
| EPS (₹) | 4.40 | 6.21 | 182.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 12.57 | 8.42 | 0.13 |
| Reserves & surplus | 36.52 | 4.36 | 9.30 |
| Shareholders' funds (net worth) | 49.09 | 12.78 | 9.43 |
| Secured loans | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 1.86 | 0.00 |
| Total debt | 0.00 | 1.86 | 0.00 |
| Total liabilities | 49.20 | 14.73 | 9.43 |
| Assets | |||
| Gross block | 13.82 | 8.72 | 4.97 |
| Net block | 7.42 | 3.81 | 4.59 |
| Capital work in progress | 0.00 | 0.00 | 0.00 |
| Investments | 16.64 | 8.00 | 4.20 |
| Inventories | 0.39 | 0.36 | 0.29 |
| Sundry debtors | 0.50 | 2.39 | 0.71 |
| Cash & bank balances | 21.21 | 0.80 | 0.89 |
| Loans & advances | 6.27 | 1.55 | 0.04 |
| Total current assets | 28.37 | 5.10 | 1.93 |
| Total current liabilities | 2.95 | 2.19 | 1.04 |
| Net working capital | 25.42 | 2.91 | 0.89 |
| Total assets | 49.20 | 14.73 | 9.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 0.80 | 0.89 | 0.00 |
| Net cash from operating activities | 3.20 | 2.79 | 5.05 |
| Net cash from investing activities | (12.60) | (2.75) | (9.51) |
| Net cash from financing activities | 29.80 | (0.12) | 5.35 |
| Net change in cash | 20.40 | (0.08) | 0.89 |
| Closing cash | 21.21 | 0.80 | 0.89 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +24.7% | +364.9% | - |
| EBITDA growth | +23.6% | +321.8% | - |
| PBT growth | +8.7% | +176.0% | +9997.0% |
| Net income growth | -2.3% | +117.5% | - |
| Profitability & leverage | |||
| Net income margin | +27.3% | +32.1% | +68.6% |
| Return on capital employed | +22.8% | +55.6% | +25.8% |
| Return on net worth | +17.9% | +47.1% | +25.5% |
| Debt / equity | 0.03 | 0.08 | 0.00 |
| Long-term debt / equity | 0.03 | 0.08 | 0.00 |
| Interest cover | 0.65 | 0.57 | 0.92 |
| Efficiency & per share | |||
| Fixed asset turnover | 1.80 | 2.38 | 0.70 |
| Inventory turnover | 54.08 | 50.06 | 12.07 |
| Debtors turnover | 14.03 | 10.50 | 4.93 |
| EPS (₹) | 4.40 | 6.21 | 182.53 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 39.05 | 15.18 | 717.10 |
Competitors of PC Diagnostics
PC Diagnostics has 10 listed competitors in our database, 7 of them funded. They include Thyrocare, Vijaya Diagnostic Centre, Suraksha Diagnostics, Igenetic and Krsnaa Diagnostics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| thyrocare.com | 1996 | Mumbai, India | $63.59M | 1,889 | Diagnostic testing centers for pathology and health screenings are operated. | |
| vijayadiagnostic.com | 1981 | Hyderabad, India | – | – | Diagnostic services are offered via a chain of centers. | |
| surakshanet.com | 2005 | Kolkata, India | $49M | 1,180 | Pathology, molecular diagnostics, and imaging services are provided. | |
| igenetic.com | 2013 | Mumbai, India | $24.04M | 7 | Provider molecular diagnostic solutions and services | |
| krsnaadiagnostics.com | 2011 | Pune, India | $23.61M | 3,703 | Chain of radiology & pathology laboratory centers | |
| aarthiscan.com | 2000 | Chennai, India | – | 1,931 | Chain of diagnostic centers | |
| medall.in | 2008 | Chennai, India | $55.1M | – | Medical diagnostic services are provided through a chain of centres. | |
| phdiagnosticcentre.com | 2001 | Pune, India | – | 251 | Provider of medical diagnostic services including blood tests, urine tests, and specialized health check-ups | |
| gd-lab.com | 2007 | Mumbai, India | $11.5M | 291 | A chain of clinical laboratories is operated for diagnostic services. | |
| healthledger.co.in | 2020 | Pune, India | $380,041 | 137 | Chain of radiology & pathology laboratory centers |
Detailed competitors of PC Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diagnostics Laboratories
10 companies that operate in the same segment as PC Diagnostics (Diagnostics Laboratories), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Diagnostic testing centers for pathology and health screenings are operated. | 1996 | Mumbai, Maharashtra, India | USD 63.59 M | USD 88.36 M | 1,950 | |
Chain of pathology and radiology labs | 1949 | Gurugram, Haryana, India | USD 13.9 M | USD 294.49 M | 5,310 | |
Home-based diagnostic tests are booked via an online platform. | 2018 | Noida, Uttar Pradesh, India | USD 116.42 M | USD 41.86 M | 2,308 | |
Pathology, radiology, wellness and clinical research services | 1995 | Mumbai, Maharashtra, India | – | – | – | |
Diagnostic centers are operated as a nationwide chain. | 1981 | Mumbai, Maharashtra, India | USD 228.2 M | USD 175.43 M | 5,180 | |
Radiology centers are operated as a nationwide chain. | 1984 | Los Angeles, California, United States | – | USD 2.04 B | 8,550 | |
DNA sequencing, bioinformatics, and multiomics services are provided. | 2013 | Bengaluru, Karnataka, India | USD 264.5 M | USD 29.55 M | 883 | |
Chain of radiology centers | 2015 | Jacksonville, United States | – | USD 749.63 M | 5,486 | |
At-home diagnostic tests are booked and collected by phlebotomists. | 2020 | Bengaluru, Karnataka, India | USD 77.12 M | USD 3.34 M | 719 | |
Biomarker analysis and diagnostic tests are offered by the laboratory. | 2012 | Gurugram, Haryana, India | USD 17.26 M | USD 11.27 M | 496 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pc Diagnostics
Complete news archive for PC Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PC Diagnostics
PC Diagnostics was founded in 2016.
PC Diagnostics is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
PC Diagnostics has 1 employees.
The primary company behind PC Diagnostics, Invicta Diagnostic Limited, reported revenue of ₹30.66 Cr for FY 2025, up 268% year on year.
PC Diagnostics delivers preventive health check-ups and diagnostic services, including pathology, imaging, and non-invasive cardiology. They operate centers across Mumbai, with affiliations to hospitals, ensuring accurate tests for full body check-ups and home blood services. Serving doctors and patients in India, they focus on advancements in diagnostics for reliable health outcomes.
PC Diagnostics's top competitors include Thyrocare, Krsnaa Diagnostics and Suraksha Diagnostics.
PC Diagnostics offers Ultrasound, X-Ray, Pathology, CT Scan, and 3 more products and services.
Yes, PC Diagnostics is publicly traded on NSE under the ticker symbol INVICTA.
PC Diagnostics is associated with 5 legal entities: Invicta Diagnostic Limited, Primacare Healthcare Llp, Invicta Diagnostic Llp and others.
The legal entities of PC Diagnostics currently have 15 directors, including Badal Kailash Naredi, Sanket Vinod Jain, Kushal Wayunandan Koli and others.